See how AbbVie Inc. and Tesla, Inc. differ across market data and performance, so you can decide which asset best fits your strategy.
$254.49
NYSE
AbbVie Inc. is a pharmaceutical company with significant exposure to immunology through Humira, Skyrizi, and Rinvoq, and to oncology through Imbruvica and Venclexta. The company was spun off from Abbott in early 2013. Its 2020 acquisition of Allergan expanded its portfolio with additional products in aesthetics, including Botox. In 2024, AbbVie further strengthened its business through the acquisitions of Cerevel in neuroscience and ImmunoGen in oncology.
Tesla, Inc. is a vertically integrated battery electric vehicle manufacturer and developer of real-world artificial intelligence software, including autonomous driving technology and humanoid robots. Its vehicle lineup includes luxury and midsize sedans, crossover SUVs, a light truck, and a semi truck. Tesla also plans to launch a sports car and introduce a robotaxi service. In 2025, the company delivered nearly 1.64 million vehicles globally. Beyond automotive operations, Tesla sells batteries for stationary energy storage across residential, commercial, and utility applications, along with solar panels and solar roofs for power generation. The company also operates a fast-charging network and an auto insurance business.